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Abstract
In patients with Plasmodium vivax malaria treated with effective blood-stage therapy,
the recurrent illness may occur due to relapse from latent liver-stage infection or rein-
fection from a new mosquito bite. Classification of the recurrent infection as either
relapse or reinfection is critical when evaluating the efficacy of an anti-relapse treat-
ment. Although one can use whether a shared genetic variant exists between baseline
and recurrence genotypes to classify the outcome, little has been suggested to use both
sharing and nonsharing variants to improve the classification accuracy. In this paper,
we develop a novel classification criterion that utilizes transition likelihoods to distin-
guish relapse from reinfection. When tested in extensive simulation experiments with
known outcomes, our classifier has superior operating characteristics. A real data set
from 78 Cambodian P. vivax malaria patients was analyzed to demonstrate the prac-
tical use of our proposed method.
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1 INTRODUCTION
The classification of infections from more than one potential
cause is critical in malaria research. Taking Plasmodium fal-
ciparum, for example, the most prevalent malaria species in
Sub-Saharan Africa, may recur due to relapse from treatment
failure or due to reinfection from new mosquito bites. The true
anti-malarial treatment efficacy cannot be determined without
knowing whether the recurrent infection is due to treatment
failure or new infection in an area of high malaria transmis-
sion (Kwiek et al., 2007; Daniels et al., 2008; Juliano et al.,
2010). Plasmodium vivax, the leading cause of malaria out-
side Africa, may similarly recur due to treatment failure or
reinfection. However, in many endemic areas such as South-
east Asian and Oceania, it often recurs due to relapse of hyp-
nozoites reactivating from the liver, as most anti-malarials are
not active against these latent liver stages of P. vivax (Lin
et al., 2015; Beck et al., 2016; Pearson et al., 2016). Indeed,
without knowing the cause of recurrent infection, determin-
ing treatment efficacy, relapse rate, and disease epidemiology
is challenging.
Given the high degree of genetic diversity and polyclonal
nature of P. vivax infections in many parts of the world, where
many clones (genetically distinct strains) exist within a human
host, a targeted amplicon deep sequencing approach provides
an opportunity for a higher precision of classification (Lin
et al., 2015). As part of a malaria cohort study conducted
from 2010 to 2011 (Lon et al., 2014), patients in Cambo-
dia found to have P. vivax were followed after treatment with
a highly efficacious artemisinin-based combination therapy,
with blood samples collected for deep sequencing at base-
line. Of 78 infected patients followed, 23 individuals devel-
oped recurrent infections. Their blood sample was collected at
the time of recurrence for another round of sequencing. It was
hypothesized that through genotyping of the initial and recur-
rent parasite isolates, one may be able to distinguish relapse
from reinfection based on variant overlap between the two
sequencing results within individuals.
Naively, one may classify the recurrent infection as relapse
if any variant in the recurrent infection is shared with the
initial infection (Nyachieo et al., 2005; Kobbe et al., 2006).
However, without considering the prevalence of the variant,
false positive misclassification likely occurs if some variants
are frequently observed in the population (Juliano et al.,
2009). Kwiek et al. (2007) treated the recurrent infection as
indeterminate if the initial and recurrent infections shared
only one variant with a prevalence of more than 10%.
However, this approach is somewhat ad hoc because the 10%
prevalence cutoff may not be generally applied to other areas,
and sharing only one variant may be rare in regions of high
transmission where the parasite population is diverse, and a
high number of variants is routinely detected in an individual
(Juliano et al., 2010). Instead, Lin et al. (2015) calculated the
reinfection probability as the product of all reinfection proba-
bilities from all shared variants and classified the recurrence
as reinfection if the probability is more than 10%. Specifically,
they calculated the reinfection probability based on a binomial
probability model (BPM) that equals to
∏
𝑗{1 − (1 − 𝑦𝑗)𝑥},
where 𝑦𝑗 is the prevalence of a shared variant and 𝑥 is
the number of variants observed in the recurrent infection.
As one can see, the probability model considers only the
possibility of shared variants occurred in the recurrence. A
nonshared variant may also occur at random in the recurrent
infection, regardless whether the recurrence is relapse or rein-
fection. This is likely due to reactivation of latent parasites
acquired from other, historical infections preceding those
captured by genotyping (Chen et al., 2007; Imwong et al.,
2007).
The presence or absence of variants in the initial and recur-
rence sequencings can naturally be described by a transition
model. However, the estimation of transition probabilities is
complicated by an unknown mixture of two models, one from
relapse and one from reinfection. Here in this paper, we pro-
pose an estimation procedure that can estimate the transition
probabilities under unknown causes of infections. The method
is first established on a statistical model that can describe the
probability of relapse in the recurrent infection. Then, through
comparison of two transition likelihoods, our novel classifi-
cation criterion utilizing the transition information can sig-
nificantly improve a classifier that uses only initial sequenc-
ing information.
The rest of the paper is organized as follows. In Section 2,
we develop a statistical model for the probability of observing
a recurrent infection in the follow-up period, which sums over
probabilities of relapse and reinfection. A likelihood-based
estimation method is utilized, with a computing solution for
high-dimensional data when the number of allelic variants
exceeds the number of subjects. Our novel classification cri-
terion is discussed in Section 3. Simulation studies in Sec-
tion 4 for both low- and high-dimensionality scenarios show
the consistency and high accuracy of our classifier. A com-
parison to the existing BPM method (Lin et al., 2015) shows
the superiority of our approach. We apply our method to the
P. vivax infection data and present part of the classification
results in Section 5. Assumptions and possible generalizations




For subject 𝑖, let 𝑿𝑖 = (𝑋𝑖1,… , 𝑋𝑖𝐽 )′ and 𝒁 𝑖 =
(𝑍𝑖1,… , 𝑍𝑖𝐽 )′ denote a 𝐽 -dimensional vector of sequencing
outcomes in the initial and recurrent infections, respectively.
Let 𝑌𝑖 be the binary indicators with 𝑌𝑖 = 1 indicating the
recurrence and 0 otherwise. In this study, we aim to classify
the recurrent infection, 𝑌𝑖 = 1, into two latent classes,
namely, relapse 𝑅𝑖 = 1 or reinfection 𝑁𝑖 = 1, assuming that
two types of infections cannot occur simultaneously. We
also assume that a third possible class, treatment failure, is
unlikely in the setting of highly efficacious therapy. Note
that the sequencing outcomes 𝒁 𝑖 in the recurrent infection
can only be observed when 𝑌𝑖 = 1, and can be different
from 𝑿𝑖 even when the recurrent infection is relapse. If a
subject does not have a recurrent infection, that is, 𝑌𝑖 = 0, the
information on 𝒁 𝑖 is not available. Through the paper, the
number of subjects from the baseline with initial sequencing
is denoted by 𝑛, and the number of subjects who have





Suppose that 𝑃 (𝑋𝑖𝑗 = 1) = 𝑝𝑗 for 𝑖 = 1,… , 𝑛, where 𝑋𝑖𝑗 = 1
indicates the presence of variant 𝑗 in the sequencing outcome
of subject 𝑖, and 𝑋𝑖𝑗 = 0 otherwise. Given a realization of the
initial sequencing outcome 𝒙𝑖 = (𝑥𝑖1,… , 𝑥𝑖𝐽 )′, the indicator







= 𝛼 + 𝒙′𝑖𝜷, (1)
where 𝜋𝑖(𝜃) = 𝑃 (𝑅𝑖 = 1|𝑿𝑖 = 𝒙𝑖), 𝜽 = (𝛼,𝜷′)′, and 𝜷 =
(𝛽1,… , 𝛽𝐽 )′ with 𝛽𝑗 = 0 indicating the 𝑗th variant is not asso-
ciated with the relapse.
However, the relapse indicator 𝑅𝑖 cannot be observed.
What can be observed is the recurrence indicator 𝑌𝑖, which
equals 1 if either relapse or reinfection occurs. Assume that
the probability of acquiring an reinfection is constant and
independent of the baseline variants 𝑿𝑖, that is,
𝑃 (𝑁𝑖 = 1|𝑅𝑖 = 0,𝑿𝑖) = 𝑃 (𝑁𝑖 = 1|𝑅𝑖 = 0) = 𝜇,
and that both infections cannot occur simultaneously, that is,
𝑃 (𝑁𝑖 = 1|𝑅𝑖 = 1,𝑿𝑖) = 0.
One can write
𝑃 (𝑌𝑖 = 1|𝑿𝑖)
= 𝑃 (𝑁𝑖 = 1, 𝑅𝑖 = 0|𝑿𝑖) + 𝑃 (𝑁𝑖 = 0, 𝑅𝑖 = 1|𝑿𝑖)
= 𝑃 (𝑁𝑖 = 1|𝑅𝑖 = 0,𝑿𝑖)𝑃 (𝑅𝑖 = 0|𝑿𝑖)
+𝑃 (𝑁𝑖 = 0|𝑅𝑖 = 1,𝑿𝑖)𝑃 (𝑅𝑖 = 1|𝑿𝑖)
= 𝜇{1 − 𝜋𝑖(𝜽)} + 𝜋𝑖(𝜽), (2)




Note that assuming constant infection rate is reasonable
because subjects who live in the same area shall be bite by
mosquitoes completely at random. The reinfection rate may
depend on risk factors. If so, we may build a regression model
relating the reinfection rate to those risk factors. Our approach
still applies after such adjustment.
2.3 Estimation method
For the binary outcome 𝑌𝑖, one can estimate the unknown
parameters minimizing the negative log-likelihood function.
However, the reinfection probability 𝜇 and baseline relapse
rate 𝛼 may not be estimable simultaneously because both
parameters are part of the baseline recurrences. To avoid
such identifiability problem, we assume the reinfection rate
is known or can be estimated via external information. Given





[𝑦𝑖 log 𝑝𝑖(𝜽) + (1 − 𝑦𝑖) log{1 − 𝑝𝑖(𝜽)}],
where 𝑦𝑖 is a realization of 𝑌𝑖 and 𝑝𝑖(𝜽) = 𝜇{1 − 𝜋𝑖(𝜽)} +
𝜋𝑖(𝜽). Under regularity conditions for maximum likelihood
estimators, one can show that ?̂? is a consistent estimator of
𝜽 and 𝑛1∕2(?̂? − 𝜽) converges in distribution to a normal vari-
able with mean 0 and variance that is the inverse of Fisher
information matrix.
In our data where the number of variants is larger than the
number of patients, we penalize the likelihood function with
an 𝐿1-penalty (Tibshirani, 1996) to enable variable selection
and avoid ill-posed minimization problem when 𝐽 > 𝑛. In par-







where 𝜆 is a tuning parameter whose optimal value will be
determined by cross-validation. There are some other choices
of penalty functions, such as elastic net penalty (Zou and
Hastie, 2005), adaptive Lasso (Zou, 2006), or folded-concave
penalty (Fan and Lv, 2011). From numerical studies, we
found that the performance of our method is not sensitive
to the choice of penalty functions. The main purpose of
penalization is to regulate the optimization problem with
high-dimensional covariates and select baseline variants that
associate with recurrence.
2.4 Computation
We develop a coordinate gradient descent algorithm (Fried-
man et al., 2010) to solve the optimization problem (3).
Let ?̃? = (𝛼, 𝜷
′
)′ be the current value of 𝜽 and 𝜗𝑖 = 𝛼 + 𝒙′𝑖𝜷.
Let 𝑓 (𝜗𝑖) = 𝑦𝑖 log 𝑝(𝜗𝑖) + (1 − 𝑦𝑖) log{1 − 𝑝(𝜗𝑖)} with 𝜗𝑖 =
𝛼 + 𝒙′𝑖𝜷, and let 𝑓
′(𝜗𝑖) and 𝑓 ′′(𝜗𝑖) denote the first and sec-
ond derivatives of the function 𝑓 with respect to 𝜗𝑖, respec-





























where 𝜗∗𝑖 = 𝜗𝑖 − 𝑓
′(𝜗𝑖)∕𝑓 ′′(𝜗𝑖), ?̃?𝑖 = −𝑓 ′′(𝜗𝑖), and 𝑐1(?̃?)
and 𝑐2(?̃?) are functions depending only on ?̃?. We then min-
imize 𝓁𝑄(𝜽; ?̃?) + 𝜆
∑𝐽
𝑗=1 |𝛽𝑗|, which becomes a regularized
















Such a problem can be solved by a standard coordinate gradi-
ent descent algorithm (Friedman et al., 2010), which is imple-
mented by R package glmnet.
The remaining tasks are to derive 𝑓 ′(𝜗𝑖) and 𝑓 ′′(𝜗𝑖). By
the definition of 𝑝(𝜗𝑖), one has 𝑝′(𝜗𝑖) = (1 − 𝜇)𝜋𝑖(𝜽){1 −
𝜋𝑖(𝜽)}, and 𝑝′′(𝜗𝑖) = (1 − 𝜇)𝜋𝑖(𝜽){1 − 𝜋𝑖(𝜽)}{1 − 2𝜋𝑖(𝜽)}.











{𝑦𝑖 − 𝑝(𝜗𝑖)}. (5)
Since
log𝑓 ′(𝜗𝑖) = log 𝑝′(𝜗𝑖) + log{𝑦𝑖 − 𝑝(𝜗𝑖)}
− log 𝑝(𝜗𝑖) − log{1 − 𝑝(𝜗𝑖)},


















Straightforwardly, the product of (5) and (6) gives 𝑓 ′′(𝜗𝑖). We
summarize the algorithm as follows:



















where 𝜗∗𝑖 = 𝜗𝑖 − 𝑓
′(𝜗𝑖)∕𝑓 ′′(𝜗𝑖), 𝜗𝑖 = 𝛼 + 𝒙′𝑖𝜷, and
?̃?𝑖 = −𝑓 ′′(𝜗𝑖).
Step 3: Update 𝜗𝑖, 𝜗
∗













Step 4: Iterate between steps 2 and 3 until convergence, that
is, the 𝐿2-norm ||?̃?new − ?̃?||2 ≤ 𝜖, where 𝜖 is a user-
defined stopping threshold. We choose 𝜖 = 0.001.
Remark that, when 𝜇 > 0, the function −𝑓 (𝜗𝑖) is not a
convex function. Therefore, solving our proposed target func-
tion (3) is a challenging nonconvex optimization problem. To
ensure stable computation of the gradient descent algorithm,
we drop negative weight ?̃?𝑖 when solving the intermediate
weighted least squares function (4) in Step 2 above. Similar to
other nonconvex optimization problems, the gradient descent
algorithm converges to a local minimum of the objective func-
tion. In the simulation studies, we find that such local minima
admit good variable selection and classification performance;
see Section 4.
3 CLASSIFICATION
We aim to classify recurrent infection (𝑌𝑖 = 1) to either
relapse (𝑅𝑖 = 1) or reinfection (𝑁𝑖 = 1). Two classifiers are
studied. The first one utilizes the initial sequencing informa-
tion and logistic regression model (1) to calculate the initial
probability estimation of the recurrence being relapse. The
second one updates the initial probability estimation using
transition likelihoods under relapse and reinfection. Through
comparison between two transition likelihoods, the second
classifier is anticipated to perform better than the first one
because more information is used.
3.1 Based on baseline information
Let 𝜉𝑖 denote the probability of being relapse given that a
recurrent infection has occurred. One can show that, based
on the recurrence probability in formula (2),
𝜉
(0)
𝑖 = 𝑃 (𝑅𝑖 = 1|𝑌𝑖 = 1,𝑿𝑖)
= 𝑃 (𝑁𝑖 = 0|𝑅𝑖 = 1,𝑿𝑖)𝑃 (𝑅𝑖 = 1|𝑿𝑖)𝑃 (𝑌𝑖 = 1|𝑿𝑖)
=
𝜋𝑖(𝜽)
𝜇{1 − 𝜋𝑖(𝜽)} + 𝜋𝑖(𝜽)
,





𝜇{1 − 𝜋𝑖(?̂?)} + 𝜋𝑖(?̂?)
.
This estimator gives a possible classification criterion via
ranking 𝜉
(0)
𝑖 . Acknowledging the interpretation of probabil-
ity, one may claim the recurrent case is (100 × 𝜉(0)𝑖 )-percent
likely to be relapse. However, one may ask for a clear cut to
identify the relapse. Barring this in mind, one can classify a
recurrent infection to be relapse if 𝜉
(0)
𝑖 > 0.5, which means
𝜋𝑖(?̂?) > 𝜇{1 − 𝜋𝑖(?̂?)} or equivalently, 𝑃 (𝑁𝑖 = 0, 𝑅𝑖 = 1|𝑌𝑖 =
1,𝑿𝑖) > 𝑃 (𝑁𝑖 = 1, 𝑅𝑖 = 0|𝑌𝑖 = 1,𝑿𝑖). The cutoff could be
chosen to optimize the operating characteristics if the true
infection type is available. Without the gold standard in this
study, we simply use 0.5 as the cutoff to choose the winner.
3.2 Updated by transition likelihoods
The variant present or absent in the baseline sequenc-
ing may not be present or absent again in the follow-up
sequencing. Recall that𝒁 𝑖 = (𝑍𝑖1,… , 𝑍𝑖𝐽 )′ is a random vari-
able for the recurrence sequencing outcomes. Assuming the
recurrent infection is a relapse, one can write 𝑍𝑖𝑗 as
𝑍𝑖𝑗 = 𝑋𝑖𝑗𝛿𝑖𝑗 + (1 −𝑋𝑖𝑗)(1 − 𝛿∗𝑖𝑗),
where 𝛿𝑖𝑗 and 𝛿
∗
𝑖𝑗 are two binary indicators that represent
repeated presence and absence of variant 𝑗 in the recur-
rence sequencing, with probability 𝑞𝑗 = 𝑃 (𝛿𝑖𝑗 = 1) and 𝑞∗𝑗 =
𝑃 (𝛿∗𝑖𝑗 = 1), respectively. Specifically, we assume that vari-
ant 𝑗 has probability 𝑞𝑗 = 𝑃 (𝑍𝑖𝑗 = 1|𝑋𝑖𝑗 = 1, 𝑅𝑖 = 1) to be
observed again in the recurrence sequencing if the variant is
observed in the initial sequencing, while the variant has proba-
bility 𝑞∗𝑗 = 𝑃 (𝑍𝑖𝑗 = 0|𝑋𝑖𝑗 = 0, 𝑅𝑖 = 1) to remain unobserved
in the recurrence sequencing if the variant is absent at the
baseline. This mechanism can be considered as a transition
model from the baseline sequencing to the follow-up sequenc-
ing outcomes, where 𝑞𝑗 and 𝑞
∗
𝑗 are transition probabilities in
a two-state transition model. If the recurrence is indeed a new
infection, we assume 𝒁 𝑖 is independent of 𝑿𝑖, and follows the
same distribution as 𝑿𝑖.
When 𝑿𝑖 and 𝒁 𝑖 are observed, parameters 𝑝𝑗 , 𝑞𝑗 , and
𝑞∗𝑗 , 𝑗 = 1,… , 𝐽 , can be estimated as follows. The probabil-
ity 𝑝𝑗 can be consistently estimated by the sample mean 𝑝𝑗 =
𝑛−1
∑𝑛
𝑖=1 𝑥𝑖𝑗 , where 𝑥𝑖𝑗 is a realization of 𝑋𝑖𝑗 . Different from
the baseline variants, the distribution of 𝑍𝑖𝑗 is a mixture of
two distributions, depending on whether the recurrent case
is relapse or reinfection. Assuming the variants are mutually
independent, we have
𝑃 (𝑍𝑖𝑗 = 1|𝑅𝑖 = 1, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)
= 𝑥𝑖𝑗𝑞𝑗 + (1 − 𝑥𝑖𝑗)(1 − 𝑞∗𝑗 ) = 𝜂(𝑥𝑖𝑗),




𝜂(𝑥𝑖𝑗)𝑧𝑖𝑗{1 − 𝜂(𝑥𝑖𝑗)}1−𝑧𝑖𝑗 ,
and




𝑗 (1 − 𝑝𝑗)
1−𝑧𝑖𝑗 .
Let 𝜙𝑅𝑖 (𝑞, 𝑞
∗) = 𝑃 (𝒁 𝑖 = 𝒛𝑖|𝑅𝑖 = 1, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖) , where
𝑞 = (𝑞1,… , 𝑞𝐽 )′ and 𝑞∗ = (𝑞∗1 ,… , 𝑞
∗
𝐽
)′, and let 𝜙𝑁𝑖 (𝑝) =
𝑃 (𝒁 𝑖 = 𝒛𝑖|𝑅𝑖 = 0, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖), where 𝑝 = (𝑝1,… , 𝑝𝐽 )′.
The mixture distribution of 𝒁 𝑖 can be written as








𝑃 (𝒁 𝑖 = 𝒛𝑖|𝑅𝑖 = 𝑟, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)
×𝑃 (𝑅𝑖 = 𝑟|𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)
= 𝜙𝑁𝑖 (𝑝)(1 − 𝜉
(0)




To obtain the maximum likelihood estimators for 𝑞 and 𝑞∗, we




log{𝜙𝑁𝑖 (𝑝)(1 − 𝜉
(0)








𝑗 (1 − 𝑝𝑗)
1−𝑧𝑖𝑗 , and 𝜉(0)𝑖 is the esti-
mated probability of relapse based on the baseline sequenc-
ing information.
Based on the transition model for the follow-up sequenc-
ing outcomes, one can derive the probability of relapse given




𝑖 = 𝑃 (𝑅𝑖 = 1|𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖,𝒁 𝑖 = 𝒛𝑖)
=
𝑃 (𝒁 𝑖 = 𝒛𝑖|𝑅𝑖 = 1, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)
×𝑃 (𝑅𝑖 = 1|𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)∑1
𝑟=0 𝑃 (𝒁 𝑖 = 𝒛𝑖|𝑅𝑖 = 𝑟, 𝑌𝑖 = 1,𝑿𝑖 = 𝒙𝑖)




𝜙𝑁𝑖 (𝑝)(1 − 𝜉
(0)












𝜙𝑁𝑖 (𝑝)(1 − 𝜉
(0)











𝜂(𝑥𝑖𝑗)𝑧𝑖𝑗{1 − 𝜂(𝑥𝑖𝑗)}1−𝑧𝑖𝑗 ,
and
𝜂(𝑥𝑖𝑗) = 𝑥𝑖𝑗𝑞𝑗 + (1 − 𝑥𝑖𝑗)(1 − 𝑞∗𝑗 ),
where 𝑞𝑗 and 𝑞
∗
𝑗 are maximum likelihood estimators solving
(7).
The estimator provides another classifier as one may claim
the recurrent case is (100 × 𝜉(1)𝑖 )-percent likely to be relapse
and classify the recurrence as relapse if 𝜉
(1)
𝑖 > 0.5. In fact,
𝜉
(1)
𝑖 can be considered as the probability that updates 𝜉
(0)
𝑖 by a




specifically, the estimated odds of relapse given the follow-up





















which updates the estimated odds from the baseline informa-
tion by multiplying the ratio of two transition likelihoods. If
𝜙𝑅𝑖 (𝑞, 𝑞
∗) > 𝜙𝑁𝑖 (𝑝), the realization of 𝒁 𝑖 more likely came
from relapse. Hence, the odds of the recurrent infection being
relapse would increase from the one that uses only base-
line information.
Note that as 𝒁 𝑖 is only available from 𝑚 subjects who have
recurrent infections, the parameters 𝑞 and 𝑞∗ cannot be solved
by the likelihood function (7) when the combined dimensions
of 𝑞 and 𝑞∗ is larger than the number of subjects 𝑚. To avoid
this, we assume the transition probabilities are the same for
each variant, that is, 𝑞1 = 𝑞2 = ⋯ = 𝑞𝐽 and 𝑞∗1 = 𝑞
∗
2 = ⋯ =
𝑞∗
𝐽
, such that there are only two scalar parameters 𝑞 and 𝑞∗ in
(7). A possible generalization that relaxes this assumption is
discussed in Section 6.
4 SIMULATION EXPERIMENTS
In this section, we demonstrate our method via simulation
experiments with various combinations of reinfection rate 𝜇,
sample size 𝑛, and number of variants 𝐽 . First, we explore
a low-dimension setting when there are only 10 variants in
both sequencings. The baseline sequencing outcomes 𝑋𝑖𝑗 ,
𝑗 = 1,… , 10, are assumed to follow a Bernoulli distribution
with success probability 𝑝𝑗 = 0.5 exp{−(𝑗 − 1)∕10}, which
mimics the distribution of variants in our real data. Two transi-
tion probabilities, 𝑞𝑗 and 𝑞𝑗 , are set to be 0.95. The probability
of acquiring a new infection is set to be 𝜇 = 0.05, 0.12, 0.25,
from low to high reinfection rates. We explore two scenarios
under which the association between the presence of the vari-
ant and relapse is different. In the first scenario, we assume
that the relapse is associated with three most prevalent vari-
ants 𝑋𝑖1, 𝑋𝑖2, 𝑋𝑖3. In the second scenario, we assume the
relapse is associated with three rarest variants 𝑋𝑖8, 𝑋𝑖9, 𝑋𝑖10.
In each scenario, we set the intercept 𝛼 = −2 in the relapse
model (1) and coefficients 𝛽𝑗 = 0.405 if the variant 𝑗 is asso-
ciated with the relapse and 𝛽𝑗 = 0 otherwise. The sample size
is set to be 𝑛 = 100, 200, 400, 800. We simulate 1000 repeti-
tions for each combination of 𝜇 and 𝑛 in each scenario. We
report the bias of the coefficient estimates to demonstrate
the consistency of our proposed estimator for the regression
coefficients. We also report operating characteristics such
as sensitivity (sens), specificity (spec), and overall accuracy
(acc) of the classifiers 𝐼(𝜉(0) > 0.5) and 𝐼(𝜉(1) > 0.5). We
also compare our method to the BPM used in Lin et al.
(2015).
T A B L E 1 Bias of regression coefficient estimation under
scenario 1
𝝁 𝒏 𝜷𝟏 𝜷𝟐 𝜷𝟑 𝜷𝟒 𝜷𝟓
0.05 100 1.129 1.243 1.181 −0.142 −0.276
200 0.114 0.044 0.093 −0.048 −0.081
400 0.026 0.014 0.041 −0.003 0.012
800 0.012 0.005 0.021 −0.004 0.007
0.12 100 3.899 3.774 3.837 −3.748 −0.519
200 0.742 0.379 0.424 −0.050 −0.341
400 0.028 0.030 0.045 −0.004 −0.010
800 0.008 0.005 0.030 −0.014 0.001
0.25 100 5.816 4.482 4.579 −0.814 −2.132
200 3.066 2.573 2.478 −0.985 −0.544
400 0.271 0.092 0.079 0.120 −0.039
800 0.014 0.028 0.029 0.001 0.007
𝝁 𝒏 𝜷𝟔 𝜷𝟕 𝜷𝟖 𝜷𝟗 𝜷𝟏𝟎
0.05 100 −0.756 −1.409 −1.295 −0.863 −0.754
200 −0.089 −0.135 −0.197 −0.135 −0.153
400 −0.022 −0.032 −0.028 −0.026 −0.043
800 −0.003 −0.015 −0.012 −0.010 −0.023
0.12 100 −3.657 −1.947 −1.914 −1.718 −5.552
200 −0.860 −0.973 −0.214 −2.913 −0.650
400 −0.049 −0.053 0.004 −0.015 −0.062
800 −0.018 −0.023 0.001 −0.001 −0.013
0.25 100 −4.738 −4.455 −3.278 −5.488 −4.870
200 −1.155 −2.339 −3.635 −2.956 −1.537
400 −0.143 −0.263 −0.225 −0.612 −0.210
800 −0.016 −0.010 −0.072 −0.037 −0.020
Tables 1 and 2 show the simulation results under the sce-
narios 1 and 2, respectively. One can see that our estimator
is consistent. When the sample size 𝑛 increases, the bias con-
verges toward 0. It is worth noting that our estimator performs
equally well in those two scenarios when either common or
rare variants are associated with the relapse. Table 3 shows
the operating characteristics of three classifiers under differ-
ent reinfection rates. One can see that using 𝐼(𝜉(0) > 0.5) as
the classifier can be overly aggressive under a low reinfec-
tion rate. Most of the recurrences are claimed as relapse and
result in high sensitivity but low specificity, especially when
the sample size is large. On the other hand, using 𝐼(𝜉(1) > 0.5)
as the classifier performs well, reaching a high degree of accu-
racy in both sensitivity and specificity. The reinfection rate is a
significant factor for the classification accuracy of our classi-
fiers. Under a high reinfection rate, the overall accuracy of the
classifier 𝐼(𝜉(0) > 0.5) is low. Correctly classifying relapse
becomes more difficult for the classifier using 𝜉(0). The same
problem occurs to 𝐼(𝜉(1) > 0.5)when the sample size is small.
However, when the sample size increases, the accuracy of
𝐼(𝜉(1) > 0.5) increases to a satisfactory level, under either
T A B L E 2 Bias of regression coefficient estimation under
scenario 2
𝝁 𝒏 𝜷𝟏 𝜷𝟐 𝜷𝟑 𝜷𝟒 𝜷𝟓
0.05 100 0.656 0.367 0.177 −0.746 −0.924
200 −0.100 −0.004 0.192 −0.178 −0.108
400 0.010 −0.019 0.004 −0.015 −0.002
800 0.009 −0.011 −0.004 −0.006 −0.006
0.12 100 −0.368 −1.593 −2.398 −1.302 −1.104
200 −0.541 −0.682 −0.138 −1.069 −2.454
400 −0.015 0.006 −0.050 −0.055 −0.002
800 −0.012 −0.007 −0.004 −0.013 0.007
0.25 100 −1.367 −2.823 −1.996 −3.290 −1.771
200 −1.325 −1.096 −1.609 −2.230 −3.028
400 −0.467 −0.876 0.152 −1.062 −0.190
800 0.012 −0.090 −0.002 −0.023 −0.019
𝝁 𝒏 𝜷𝟔 𝜷𝟕 𝜷𝟖 𝜷𝟗 𝜷𝟏𝟎
0.05 100 −1.965 −1.708 0.768 0.700 1.537
200 −0.257 −0.220 0.072 −0.090 0.080
400 −0.017 −0.033 0.008 −0.017 0.000
800 −0.003 −0.010 0.006 −0.008 −0.001
0.12 100 −3.751 −6.018 1.511 0.675 −0.877
200 −1.751 −1.306 0.509 0.586 0.267
400 −0.074 −0.150 0.041 −0.029 −0.074
800 −0.019 −0.008 0.006 0.001 0.001
0.25 100 −3.384 −3.217 2.677 1.502 1.927
200 −4.561 −3.112 1.756 −0.204 1.783
400 −1.325 −1.724 0.370 −0.042 0.158
800 −0.293 −0.091 0.031 −0.078 −0.050
common or rare variants scenario. In comparison to the BPM
method (Lin et al., 2015), one can see that the BPM’s perfor-
mance remains unchanged under different reinfection rates.
The method generally performs better than our classifier when
the sample size is small. However, when the sample size is
large or when the reinfection rate is low, our classifier per-
forms much better than the BPM method. Note that the cutoff
probability used in the BPM can be arbitrary and may depend
on the prevalence of the shared variant, which is unknown in
practice. It is not clear how to select the best cutoff for their
method. We used 10% as suggested in Lin et al. (2015).
In addition, we performed a simulation study when the
number of variants exceeds the sample size. We simulate base-
line and follow-up sequencing outcomes from the same dis-
tribution as in the low-dimensional case. We consider two
combinations of 𝑛 and 𝐽 for (𝑛, 𝐽 ) = (100, 200) and (𝑛, 𝐽 ) =
(200, 400) and three reinfection rates for 𝜇 = 0.05, 0.12, 0.25.
We also consider two scenarios of how the variants associate
with relapse. In scenario 3, the relapse is associated with five
most prevalent variants through model (1), where 𝛼 = −1 and
𝜷 = (0.2, 0.2, 0.2, 0.2, 0.2, 0,… , 0)′. In scenario 4, the relapse
is associated with five relatively rare variants, where 𝛼 = −1
and 𝜷 = (0,… , 0, 0.2, 0.2, 0.2, 0.2, 0.2, 0,… , 0)′ with the 10
most prevalent variants not associated with relapse. Aver-
age sensitivity (sens), specificity (spec), and overall accuracy
(acc) of the two classifiers are reported in Table 4 for each
scenario. We also report average bias (Bias), which is defined
by (1∕𝐽 )
∑𝐽
𝑗=1 |𝛽𝑗 − 𝛽𝑗|, number of true positives (TP), and
number of true negatives (TN) to evaluate the variable selec-
tion performance of our method.
Table 4 shows that our method still works well when 𝐽 is
much larger than 𝑛. The performance of the classifier 𝐼(𝜉(1)𝑖 >
0.5) is much better than that of the classifier 𝐼(𝜉(0)𝑖 > 0.5).
When the reinfection rate is relatively high, both classifiers
suffer lower accuracy under this more difficult situation. The
performance of the classifier 𝐼(𝜉(1)𝑖 > 0.5), however, remains
acceptable. Moreover, our method identifies most of the vari-
ants that are associated with the relapse, that is, its TP propor-
tion is high, regardless of whether they are prevalent or rare,
while controlling the selection of true negatives at a satisfac-
tory level.
5 REAL DATA ANALYSIS
Given the high degree of genetic diversity and polyclonal
nature of P. vivax infections in Cambodia, many clones
or strains exist within a human host. A targeted amplicon
deep sequencing approach was chosen to genotype initial
and recurrent isolates from P. vivax patients enrolled in a
malaria cohort and treatment study conducted in northern
Cambodia from 2010 to 2011 (Lon et al., 2014; Lin et al.,
2015). Subjects found to have P. vivax malaria were treated
with dihydroartemisinin-piperaquine (DP), then followed for
recurrence with weekly blood smears for six weeks and with
a monthly blood smear after that. Of 78 P. vivax-infected sub-
jects followed for a median of 115 days, 23 individuals, or
approximately one third of the cohort, developed a recurrent
infection. These recurrences likely represent relapse or rein-
fection, because treatment failure with DP is unlikely. Dur-
ing the follow-up, six subjects suffered second recurrences,
and one subject suffered a third recurrent infection. Hence, a
total of 30 recurrent infections were available for the follow-
up genotype analysis. In combination with 78 subjects at the
baseline, there are 108 isolates available for the genotype anal-
ysis. To avoid the bias due to length of follow-up, we only use
78 baseline sequencings (𝑛 = 78) to estimate the parameters
in relapse model (1), with 23 positive responses (
∑𝑛
𝑖=1 𝑌𝑖 =
23). However, in order to utilize as much information as pos-
sible, we include those 7 second or third recurrences in the
estimation of transition probabilities 𝑞 and 𝑞∗, using their most
recent sequencing as the baseline sequencing. This results in
30 pairs of baseline and recurrence sequencings in the log-
likelihood function (7) with 𝑚 = 30.






Scenario 𝝁 𝒏 sens spec acc sens spec acc sens spec acc
1 0.05 100 89.1 83.3 88.2 89.6 12.0 76.5 93.2 82.4 91.2
200 89.2 83.7 88.3 97.0 3.8 81.8 98.4 87.2 96.5
400 89.3 84.2 88.5 99.5 0.7 83.4 98.8 87.8 97.0
800 89.4 84.0 88.5 100.0 0.0 83.7 98.9 88.3 97.2
0.12 100 88.9 84.4 87.5 64.7 38.2 56.1 73.0 79.5 75.0
200 89.1 84.2 87.5 78.4 25.3 60.9 93.2 91.2 92.5
400 89.2 84.2 87.6 87.0 16.8 63.9 97.4 92.0 95.6
800 89.3 84.1 87.6 92.2 11.5 65.7 97.6 92.3 95.9
0.25 100 89.1 84.4 86.7 44.3 58.5 51.6 50.8 72.8 61.9
200 89.4 84.3 86.8 46.1 57.6 52.0 71.1 90.1 80.8
400 89.3 84.4 86.9 50.9 55.1 53.1 92.0 94.4 93.2
800 89.4 84.3 86.8 53.0 55.3 54.2 95.7 94.7 95.2
2 0.05 100 89.2 85.1 88.3 81.4 19.8 68.5 85.8 79.5 84.3
200 89.3 84.9 88.4 92.3 8.3 74.9 96.7 88.4 94.9
400 89.4 84.5 88.4 98.2 2.0 78.5 98.4 88.8 96.4
800 89.5 84.2 88.5 99.8 0.2 79.3 98.5 89.5 96.6
0.12 100 89.1 84.5 87.2 55.3 48.0 52.4 61.9 74.4 66.6
200 89.2 83.9 87.1 63.3 39.3 53.7 83.9 90.0 86.3
400 89.5 83.9 87.3 73.8 29.7 56.4 96.2 93.0 94.9
800 89.6 84.0 87.4 80.2 23.6 57.8 97.0 93.4 95.6
0.25 100 89.3 84.1 86.3 41.1 62.5 53.6 44.6 70.5 59.5
200 89.6 84.1 86.4 35.6 67.5 54.1 54.7 87.3 73.6
400 89.8 84.2 86.5 35.9 67.7 54.3 80.8 94.6 88.7
800 89.7 84.2 86.5 33.7 71.7 55.6 94.0 95.5 94.9







𝝁 (𝒏, 𝑱 ) Bias TP TN sens spec acc sens spec acc
0.05 (100,200) 0.11 5 146 100 0 92.0 100 80.6 98.3
(200,400) 0.03 4 332 100 0 92.2 99.0 97.0 98.8
0.12 (100,200) 0.07 5 157 99.0 1.3 82.3 100 69.1 94.6
(200,400) 0.02 5 353 99.8 0.1 83.2 99.0 85.1 96.7
0.25 (100,200) 0.09 5 156 89.1 11.9 65.9 100 75.2 92.6






𝝁 (𝒏, 𝑱 ) Bias TP TN sens spec acc sens spec acc
0.05 (100,200) 0.01 5 194 100 0 91.9 100 50 95.2
(200,400) 0.01 5 395 100 0 93.6 100 80 98.2
0.12 (100,200) 0.07 5 157 90.9 0 76.9 97.6 57.1 91.1
(200,400) 0.02 5 354 97.4 0 83.5 97.7 88.9 96.7
0.25 (100,200) 0.05 5 174 70.5 27.5 59.2 86.7 74.3 80.9
(200,400) 0.11 5 280 71.8 24 58.8 96.3 83.3 92
Targeted deep sequencing was performed on DNA
extracted from filter paper blood spots collected by finger
prick. A nested polymerase chain reaction (PCR) assay was
used to amplify a 117-base pair variable portion of the P. vivax
merozoite surface protein 1 (pvmsp1) gene based on previ-
ous work showing great nucleotide diversity across this region
(Parobek et al., 2014). Samples were amplified in duplicate
and individually tagged, then pooled and sequenced on the
Ion Torrent platform from Life Technologies. The Pvmsp1
sequence variants were determined by SeekDeep, a bioin-
formatics pipeline that uses a clustering method to construct
the most likely haplotypes within a patient while removing
false haplotypes due to PCR or sequencing error (Hathaway
et al., 2018). For each subject, pvmsp1 haplotypes that were
present in two independent duplicate PCR samples at ≤0.5%
frequency were counted as unique variants. Consensus hap-
lotypes were each assigned a unique population identifier
based on their prevalence in the cohort, namely, CAM.00 to
CAM.66 with CAM.00 being the most prevalent pvsmp1 vari-
ant encountered. In total, 67 unique pvmsp1 variants were
detected across 108 isolates. Nine common variants appeared
in at least 10% of individuals, while two-thirds of variants
appeared in only one isolate. In-host genetic diversity was also
high, as 90% of initial infections contained multiple variants,
displaying an average of 3.6 co-circulating variants.
We used the penalized likelihood model with an 𝐿1-
penalty, as shown in (3), with 5% reinfection rate. We report
variants in the initial and recurrence sequencing, their esti-
mated coefficients 𝜷 in model (1), prevalence of the variants,
two classification probability estimates, and classification
results based on 𝜉
(1)
𝑖 and BPM method. Variants with a
nonzero estimated coefficient are considered to be associated
with relapse. Using the profiled likelihood function (7), the
maximum likelihood estimates for the transition probability
are 𝑞 = 0.387 and 𝑞∗ = 0.987.
Table 5 shows part of the classification results. A com-
plete list of the classification results is shown in the Sup-
porting Information. First, one can see that the recurrence is
likely classified as reinfection if variants in the recurrence are
prevalent and not observed in the initial sequencing. Taking
151→151R pair, for example, the nonsharing variant CAM.00
that appeared in the recurrence sequencing is the most preva-
lent variant in the sample, suggesting that the recurrence
is likely reinfection. Second, the high transition probability
𝑞∗ = 0.987 suggests that an unobserved variant in the ini-
tial sequencing likely remains unobserved in the recurrence
sequencing if the recurrence is a relapse. This explains why
152→152R pair is classified as reinfection. The appearance
of prevalent variants CAM.05 and CAM.07 in the recurrence






Some recurrence pairs tend to have more diverse and abun-
dant minority variants. Many variants tend to be nonshar-
ing due to this abundance. For example, both 80→80R pair
and 125→125R pair have multiple variants in the recurrence
sequencing that did not appear in the initial sequencing, result-
ing in a low value of 𝜉
(1)
𝑖 and reinfection as the classification
result. It is worth noting that, nonsharing variants in the ini-
tial sequencing have little impact on 𝜉
(1)
𝑖 . Taking 36→36R, for
example, the pair is still classified as relapse even when seven
initial variants were not observed in the recurrence sequenc-
ing. The classification probability 𝜉
(1)
𝑖 only slightly decreases
from 𝜉
(0)
𝑖 . This tendency can be explained by a low value of
transition probability estimate 𝑞 = 0.387. If 𝑞 is small, it is not
unusual to see a variant in the initial sequencing not observed
in the recurrence sequencing if the infection is a relapse pair
like 36→36R. In contrast, even though the 80R→80RR pair
has five sharing variants in the initial sequencing, the clas-
sification probability 𝜉
(1)
𝑖 decreases significantly from 𝜉
(0)
𝑖
because one nonsharing variant in the recurrence sequencing,
CAM.04, is prevalent.
When comparing our method to the BPM, disparity
occurs when prevalent variants appeared only in the recur-
rence sequencing. As discussed earlier, the 152→152R and
80R→80RR pairs are classified as reinfection by our method
because nonsharing variants appeared in recurrence sequenc-
ing are prevalent. The BPM method classifies them as relapse
because more than one prevalent variant overlapped in both
sequencings, such as CAM.00 and CAM.01 in the 152→152R
pair, and CAM.00, CAM.02, and CAM.06 in the 80R→80RR
pair. Contrarily, the BPM method likely classifies a recurrent
infection to reinfection if there is only one sharing variant
that is prevalent, such as CAM.00 in the 96→96R pair. Our
method otherwise classifies the pair as relapse because there
are not enough nonsharing variants appeared in the recur-
rence sequencing. In summary, the classification result of
80→80R pair demonstrates the flaw of BPM. When multi-
ple prevalent nonsharing variants (such as CAM.01, CAM.02,
and CAM.03) appears in the recurrence, it is more likely the
recurrence is reinfection, not relapse. A method like BPM
considering only shared variants ignores this possibility and
likely misclassifies the case.
Note that, from a statistical point of view, the analysis is
sensitive to the selection of background reinfection rate. If the
reinfection rate is misidentified, the maximum likelihood esti-
mator of the coefficients in model (1) may not be consistent, as
well as the classification probability 𝜉
(0)
𝑖 calculated from these
estimators. The classification probability 𝜉
(1)
𝑖 may not be con-
sistent as well because it is established on the initial classifi-
cation probability 𝜉
(0)
𝑖 . In this data analysis, the classification
result based on 𝜉
(1)
𝑖 is quite robust when the reinfection rates is
less than 10%. Meanwhile, an in vivo study on the dynamics of
P. vivax infection suggests that up to 96% of the P. vivax infec-
tion is due to relapse in individuals living in the endemic areas
in Thailand (Adekunle et al., 2015). Cambodia is in Southeast
T A B L E 5 Classification results for recurrence pairs using our method and binomial probability model
Initial Recurrence Variant Proposed BPM





36→ 36R CAM.00 1.833 0.960 CAM.01 0.269 0.870 Relapse Relapse
CAM.01 0.469 CAM.02 0.410
CAM.02 0.892 CAM.07 0.192







80 → 80R CAM.00 1.833 0.992 CAM.00 0.590 0.000 Reinfection Relapse
CAM.04 3.519 CAM.01 0.269
CAM.05 −1.085 CAM.02 0.410
CAM.08 0.395 CAM.03 0.295
CAM.09 0 CAM.05 0.231
CAM.24 2.954 CAM.06 0.231




80R→ 80RR CAM.00 1.833 0.673 CAM.00 0.590 0.340 Reinfection Relapse
CAM.01 0.469 CAM.02 0.410
CAM.02 0.892 CAM.04 0.346
CAM.03 0 CAM.06 0.231
CAM.05 −1.085 CAM.08 0.154
CAM.06 −1.416 CAM.12 0.064




96 → 96R CAM.00 1.833 0.979 CAM.00 0.590 0.992 Relapse Reinfection
CAM.02 0.892 CAM.30 0.013
CAM.04 3.519
CAM.08 0.395










T A B L E 5 (Continued)
Initial Recurrence Variant Proposed BPM





151 → 151R CAM.03 0 0.030 CAM.00 0.590 0.005 Reinfection Reinfection
CAM.05 −1.085 CAM.08 0.154
CAM.08 0.395 CAM.14 0.026
152 → 152R CAM.00 1.833 0.379 CAM.00 0.590 0.018 Reinfection Relapse
CAM.01 0.469 CAM.01 0.269
CAM.05 0.231
CAM.07 0.192
Asia and geographically adjacent to Thailand. Assuming 5%
reinfection rate in this area is reasonable. Interestingly, from
the complete list of our classification result in the Supporting
Information, 23 individuals had recurrent infections among 78
subjects at the baseline. Among those 23 subjects, 10 subjects
are classified as reinfections by our algorithm. The reinfection
rate 𝜇 = 𝑃 (𝑁𝑖 = 1|𝑅𝑖 = 0) may be estimated at 10/(78-13) =
15%, which is higher than the literature suggests.
6 DISCUSSION
In this paper, we propose a novel classification method that
is model-based and utilizes transition likelihoods to classify
recurrent P. vivax infections as either relapse or reinfection.
Previous work used only shared variants to calculate the rein-
fection probability. Here, we show that nonshared variants are
also informative. Both simulation studies and real data anal-
ysis support the feasibility and practical use of our classi-
fier. Some assumptions and generalizations of our method are
worth of discussion.
First, we assume that the reinfection rate 𝜇 is known or
can be correctly specified. Model misspecification on 𝜇 can
be problematic for both regression coefficient estimation
and classification probability calculation when an incorrect
value is used. Through simulation experiments listed in our
Supporting Information, one can see the impact of the mis-
specification is apparent when the sample size is small. When
the sample size is large, however, the bias in the coefficient
estimation diminishes, and the performance of our classifier
improves. Our approach is robust to the misspecification of
𝜇 when the sample size is large. As one can imagine, bias
more likely occurs to the estimation of intercept 𝛼 because
both 𝜇 and 𝛼 represent some sense of baseline occurrence
rates. Underestimation of 𝜇 shall lead to overestimation of
𝛼, and overestimation of 𝜇 shall lead to underestimation
of 𝛼 to balance the overall baseline occurrence rate. Such
tendency in bias can be seen in our simulation results in the
Supporting Information. Meanwhile, although misspecifica-
tion on 𝜇 leads to biased estimation of 𝜉
(0)
𝑖 , the classification
performance of 𝜉
(1)
𝑖 utilizing transition likelihoods is mildly
affected when the reinfection rate is underestimated. Even
when the reinfection rate is overestimated, the accuracy of
the classifier 𝐼(𝜉(1)𝑖 > 0.5) can still reach a satisfactory level.
Second, we assume the occurrence of the variants is inde-
pendent. This assumption can be checked in our real data.
Using Fisher’s exact tests for presence/absence of any two
of 13 most frequent variants, the minimum 𝑝-value is 0.0048
and only 10 out 78 pairs have 𝑃 -value smaller than 0.05.
After Benjamini-Hochberg adjustment for multiple compar-
isons, none of the 𝑃 -values is smaller than 0.05. The inde-
pendence assumption is not significantly violated in our case.
Finally, we assume the transition probabilities are equal




This assumption can be relaxed using external information
to model the transition probabilities. Specifically, one can
assume the probability follow a logistic model log{𝑞𝑗∕(1 −
𝑞𝑗)} = 𝑊 ′𝑗 𝛾 and log{𝑞
∗
𝑗 ∕(1 − 𝑞
∗
𝑗 )} = 𝑊
′
𝑗 𝛾
∗, where 𝑊𝑗 is a
column vector of external covariates, and 𝛾 and 𝛾∗ are col-
umn vectors of regression coefficients. In our case, reading
frequency of the variant may be the covariate that is asso-
ciated with the transition of the variants. It is worth noting
that we assume the transition starts from a new infection to
either relapse or reinfection. However, in our real data, there
are seven second or third recurrent infections. Although in
the real data analysis we treated the most recent infection as
the initial infection, the recurrent infection may depend on
multiple previous events in this case. The modeling is much
more complicated, considering the status of previous infec-
tions is unknown except for the baseline infection. It is not
clear whether a relapse infection could be associated with the
transition probability of the variants. One possible approach
is to include the relapse indicator, 𝑅𝑖, in the logistic model for
𝑞𝑗 and 𝑞
∗
𝑗 , as part of covariates 𝑊𝑗 . However, because 𝑅𝑖 is
not observable, it is not clear how 𝛾 and 𝛾∗ can be estimated.
We leave it for future research.
Our current analysis considers only recurrence indicator
without time domain involved. The causes of the recurrent
infection can actually be seen as competing risks, for which
one observes the event occurrence of either relapse or
reinfection. In our case, the cause of the event is unknown
in all of the events, so the challenge remains as how one can
derive the classification probability using a hazard model
and transition likelihoods to classify the recurrent infections
incorporating the time to infection.
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